The biotechnology market in the UK is experiencing robust growth, driven by technological advancements and increased investments in healthcare. As of 2024, the market is valued at approximately £23.4 billion, with a compound annual growth rate (CAGR) of 8.1% over the past five years.
Several factors contribute to this positive outlook. The UK government has been a strong supporter of the biotechnology sector, providing significant funding for research and development (R&D) with a focus on the ‘Golden Triangle’ where 40% of public R&D spending is concentrated. This region is home to many biotech companies that benefit from close collaboration with leading universities and research institutions.
The biotechnology sector in the UK is diverse, encompassing human health products, agricultural and food-enhancement products, and animal health products. Human health products, including biotechnology-derived proteins, antibodies, and genetic therapies, represent the largest segment. The demand for these products is driven by the need for innovative solutions to medical, agricultural, and industrial challenges.
Looking ahead to 2025, the UK biotechnology market is poised to maintain its growth trajectory. Key trends include the increasing integration of artificial intelligence and machine learning in biotech research, which enhances the efficiency and accuracy of drug discovery and development. These trends indicate a vibrant and growing biotech sector in the UK and EU, driven by substantial financial investments and a strong demand for skilled professionals. We also see the post COVID working practices in flux, with some organisations looking to return to the office, and others happy with remote working which makes the challenge for Talent even more intense.
Despite facing competition from the US and China, the UK’s strong government support and strategic investments position it well for continued growth. The biotechnology sector is expected to play a crucial role in addressing global health challenges and advancing scientific knowledge in the coming years.
At Cpl, we have seen robust growth in the SME sector, while the largest organisations, more subject to economic forces appear to me more cautious. We expect contractor hiring numbers to continue to grow, offering our clients a more flexible hiring option as confidence slowly comes back to the market. There is a definite requirement to hire for a lot of organisations, and we do expect budgets to free up significantly after a plateau in 2024.
For the full report click here
Drew Jones - Operations Director - Cpl Life Sciences| Cpl UK